Effect of Intraoperative Aprotinin Administration on Post Cardiac Surgery Optic Nerve and Retinal Thickness.
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00395369 |
Recruitment Status
: Unknown
Verified November 2006 by Soroka University Medical Center.
Recruitment status was: Not yet recruiting
First Posted
: November 2, 2006
Last Update Posted
: November 3, 2006
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cardiac Surgery | Drug: intraoperative aprotinin administration | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Enrollment : | 30 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Study Start Date : | December 2007 |

- optical coherance tomography findings

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Senior |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- patients admited for coronary artery bypass surgery
Exclusion Criteria:
Preoperative:
- Patients requiring concomitant noncoronary procedures.
- Urgent operation.
- Intra aortic balloon pump
- Presence of allergy to aprotinin or bleeding diathesis.
- Previous CVA.
- Previous eye operation.
- Glaucoma.
- Retinopathy.
Postoperative:
- Postoperative CVA.
- Postoperative critical condition precluding safe performance of OCT examination.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00395369
Contact: Dan Abramov, MD | 97286400962 | danab3@clalit.org.il |
Israel | |
Soroka Medical Center | Active, not recruiting |
Beer Sheva, Israel, 84101 |
Principal Investigator: | Dan Abramov, MD | Soroka University Medical Center |
ClinicalTrials.gov Identifier: | NCT00395369 History of Changes |
Other Study ID Numbers: |
SOR439106CTIL |
First Posted: | November 2, 2006 Key Record Dates |
Last Update Posted: | November 3, 2006 |
Last Verified: | November 2006 |
Keywords provided by Soroka University Medical Center:
aprotinin cardiac surgery neurological dysfunction optical coherance tomography |
Additional relevant MeSH terms:
Aprotinin Hemostatics Coagulants Trypsin Inhibitors |
Serine Proteinase Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |